MTOR and hepatocellular carcinoma: In addition, the sgPten/c-Met murine HCC model shows high levels of mTORC1 and mTORC2 activities and might represent a valid preclinical tool for testing the therapeutic efficacy of novel mTOR inhibitors in HCC [117].